Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis

European Journal of Surgical Oncology

Volumn 43, Issue 1, 2017, Pages 144-149

  Leung, V ^a   Huo, Y R ^a   Liauw, W ^b   Morris, D L ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

Author keywords

Colorectal cancer; HIPEC; Mitomycin C; Oxaliplatin; Peritoneal carcinomatosis; Peritoneal metastasis; Peritonectomy

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MITOMYCIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; PLATINUM COMPLEX;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; COHORT ANALYSIS; COLORECTAL CANCER; COMPARATIVE EFFECTIVENESS; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; FEMALE; HEATED INTRAPERITONEAL CHEMOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERITONECTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; AGED; CANCER GRADING; CANCER STAGING; COLORECTAL TUMOR; PATHOLOGY; PERITONEAL NEOPLASMS; PROCEDURES; REGIONAL PERFUSION; SECONDARY; SURVIVAL RATE; THERMOTHERAPY; TREATMENT OUTCOME;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM GRADING; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 85002750288     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2016.09.015     Document Type: Article

References (47)

1. 1 Jayne, D.G., Fook, S., Loi, C., Seow-Choen, F., Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89:12 (2002), 1545–1550.
2. 2 Segelman, J., Granath, F., Holm, T., Machado, M., Mahteme, H., Martling, A., Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 99:5 (2012), 699–705.
3. 3 Lemmens, V.E., Klaver, Y.L., Verwaal, V.J., Rutten, H.J., Coebergh, J.W.W., de Hingh, I.H., Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 128:11 (2011), 2717–2725.
4. 4 Klaver, Y.L.B., Leenders, B.J.M., Creemers, G.-J., et al. Addition of biological therapies to palliative chemotherapy prolongs survival in patients with peritoneal carcinomatosis of colorectal origin. Am J Clin Oncol 36:2 (2013), 157–161.
5. 5 Kerscher, A.G., Chua, T.C., Gasser, M., et al. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer 108 (2013), 1432–1439.
6. 6 Zani, S., Papalezova, K., Stinnett, S., Tyler, D., Hsu, D., Blazer, D.G., Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy. J Surg Oncol 107:4 (2013), 307–311.
7. 7 Hompes, D., Aalbers, A., Boot, H., et al. A prospective pilot study to assess neoadjuvant chemotherapy for unresectable peritoneal carcinomatosis from colorectal cancer. Colorectal Dis 16:8 (2014), O264–O272.
8. 8 Sugarbaker, P.H., Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 14:3 (1998), 254–261.
9. 9 Piso, P., Bektas, H., Werner, U., et al. Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma. Eur J Surg Oncol 27:3 (2001), 286–290.
10. 10 Verwaal, V.J., van Ruth, S., de Bree, E., et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:20 (2003), 3737–3743.
11. 11 Beaujard, A.C., Glehen, O., Caillot, J.L., et al. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer 88:11 (2000), 2512–2519.
12. 12 Loggie, B.W., Fleming, R.A., McQuellon, R.P., Russell, G.B., Geisinger, K.R., Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 66:6 (2000), 561–568.
13. 13 Witkamp, A.J., de Bree, E., Kaag, M.M., et al. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer 37:8 (2001), 979–984.
14. 14 Dubé, P., Sideris, L., Law, C., et al. Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms. Curr Oncol, 22(2), 2015, e100.
15. 15 Esquivel, J., Sticca, R., Sugarbaker, P., et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Ann Surg Oncol 14:1 (2007), 128–133.
16. 16 Kusamura, S., Dominique, E., Baratti, D., Younan, R., Deraco, M., Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol 98:4 (2008), 247–252.
17. 17 Sugarbaker, P.H., Van der Speeten, K., Stuart, O.A., Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer. World J Gastrointest Oncol 2:1 (2010), 19–30.
18. 18 Ceelen, W.P., Påhlman, L., Mahteme, H., Pharmacodynamic aspects of intraperitoneal cytotoxic therapy. Cancer Treat Res 134 (2007), 195–214.
19. 19 De Gramont, Ad, Figer, A., Seymour, M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:16 (2000), 2938–2947.
20. 20 Makatsoris, T., Kalofonos, H.P., Aravantinos, G., et al. A phase II study of capecitabine plus oxaliplatin (XELOX). Int J Gastrointest cancer 35:2 (2005), 103–109.
21. 21 Alkis, N., Demirci, U., Benekli, M., et al. Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure. J BUON 16:1 (2010), 80–83.
22. 22 Michalaki, V., Gennatas, S., Gennatas, C., Mitomycin C and UFT/leucovorin as salvage treatment in patients with advanced colorectal cancer. J BUON 15:2 (2009), 270–273.
23. 23 Hompes, D., D'Hoore, A., Wolthuis, A., et al. The of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. J Surg Oncol 109:6 (2014), 527–532.
24. 24 Cavaliere, F., De Simone, M., Virz, S., et al. Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. Eur J Surg Oncol 37:2 (2011), 148–154.
25. 25 Ceelen, W., Van Nieuwenhove, Y., Putte, D.V., Pattyn, P., Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. Ann Surg Oncol 21:9 (2014), 3023–3028.
26. 26 Prada-Villaverde, A., Esquivel, J., Lowy, A.M., et al. The American Society of peritoneal surface malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol 110:7 (2014), 779–785.
27. 27 Zenasni, F., Botella, M., Elias, D., et al. The long-term impact of hyperthermic intraperitoneal chemotherapy on survivors treated for peritoneal carcinomatosis: a cross-sectional study. Support Care Cancer 17:10 (2009), 1255–1261.
28. 28 Elias, D.M., Ouellet, J.F., Intraperitoneal chemohyperthermia: rationale, technique, indications, and results. Surg Oncol Clin N Am 10:4 (2001), 915–933.
29. 29 Raft, J., Parisot, M., Marchal, F., et al. Impact of the hyperthermic intraperitoneal chemotherapy on the fluid-electrolytes changes and on the acid-base balance. Ann Fr Anesth Reanim 29:10 (2010), 676–681.
30. 30 Votanopoulos, K., Ihemelandu, C., Shen, P., Stewart, J., Russell, G., Levine, E.A., A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res 179:1 (2013), e133–e139.
31. 31 Rueth, N.M., Murray, S.E., Huddleston, S.J., et al. Severe electrolyte disturbances after hyperthermic intraperitoneal chemotherapy: oxaliplatin versus mitomycin C. Ann Surg Oncol 18:1 (2011), 174–180.
32. 32 Randle, R.W., Swett, K.R., Swords, D.S., et al. Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol 21:5 (2014), 1474–1479.
33. 33 Jacquet, P., Sugarbaker, P., Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Sugarbaker, P., (eds.) Peritoneal carcinomatosis: principles of management. Cancer treatment and research, vol. 82, 1996, Springer, US, 359–374.
34. 34 Sugarbaker, P.H., Peritonectomy procedures. Ann Surg 221:1 (1995), 29–42.
35. 35 Greene, F.L., AJCC cancer staging manual. 2002, Springer.
36. 36 Hamilton, S.R., Aaltonen, L.A., World Health Organisation classification of tumours: pathology and genetics of tumours of the digestive system. 2000, IARC Press, Lyon.
37. 37 Elias, D., Bonnay, M., Puizillou, J., et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 13:2 (2002), 267–272.
38. 38 Pestieau, S.R., Belliveau, J.F., Griffin, H., Stuart, O.A., Sugarbaker, P.H., Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies. J Surg Oncol 76:2 (2001), 106–114.
39. 39 Piché, N., Leblond, F.A., Sidéris, L., et al. Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model. Ann Surg 254:1 (2011), 138–144.
40. 40 Van Ruth, S., Verwaal, V., Zoetmulder, F., Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am 12:3 (2003), 771–780.
41. 41 Elias, D., Raynard, B., Farkhondeh, F., et al. Peritoneal carcinomatosis of colorectal origin: long-term results of intraperitoneal chemohyperthermia with oxaliplatin following complete cytoreductive surgery. Gastroentérologie clinique Biol 30:10 (2006), 1200–1204.
42. 42 Rouers, A., Laurent, S., Detroz, B., Meurisse, M., Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: higher complication rate for oxaliplatin compared to Mitomycin C. Acta Chir Belg 106:3 (2006), 302–306.
43. 43 Votanopoulos, K.I., Swords, D.S., Swett, K.R., et al. Obesity and peritoneal surface disease: outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colon primary tumors. Ann Surg Oncol 20:12 (2013), 3899–3904.
44. 44 Ceelen, W.P., Peeters, M., Houtmeyers, P., Breusegem, C., De Somer, F., Pattyn, P., Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis. Ann Surg Oncol 15:2 (2008), 535–541.
45. 45 Valenzuela, B., Nalda-Molina, R., Bretcha-Boix, P., et al. Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosis. AAPS J 13:1 (2011), 72–82.
46. 46 Pérez-Ruixo, C., Valenzuela, B., Peris, J.E., et al. Neutrophil dynamics in peritoneal carcinomatosis patients treated with cytoreductive surgery and hyperthermic intraperitoneal oxaliplatin. Clin Pharmacokinet 52:12 (2013), 1111–1125.
47. 47 Cao, C., Yan, T.D., Black, D., Morris, D.L., A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 16:8 (2009), 2152–2165.